The cellular delivery of antisense oligonucleotides and ribozymes

Drug Discovery Today

Volumn 6, Issue 6, 2001, Pages 303-315

  Hughes, Marcus D ^a   Hussain, Majad ^a   Nawaz, Qamar ^a   Sayyed, Pakeeza ^a   Akhtar, Saghir ^a,b  

^a ASTON UNIVERSITY   (United Kingdom)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; ANTISENSE OLIGONUCLEOTIDE; CARRIER PROTEIN; DENDRIMER; LIPOSOME; MICROSPHERE; NANOPARTICLE; NUCLEIC ACID; POLYMER; RIBOZYME;

ANIMAL EXPERIMENT; CELL TRANSPORT; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; NONHUMAN; REVIEW;

EID: 0035282789     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)00326-3     Document Type: Review

References (116)

1. Oligonucleotide therapeutics: clothing the emperor
2. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development
3. Recent developments in hepatitis C antiviral research 1999-2000
4. Oligonucleotides as inhibitors of human immunodeficiency virus
5. Preclinical and clinical pharmacology of antisense oligonucleotides
6. In vivo studies with antisense oligonucleotides
7. The delivery of antisense therapeutics
8. On finding all suboptimal foldings of an RNA molecule
9. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
10. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
11. Selecting optimal antisense reagents
12. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides
13. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
14. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity
15. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts
16. Probing accessible sites for ribozymes on human acetylcholinesterase RNA
17. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H
18. Analysing sequence by hybridization to oligonucleotides on a large scale
19. Arrays of complementary oligonucleotides for analyzing the hybridization behavior of nucleic acids
20. Selecting effective antisense reagents on combinatorial oligonucleotide arrays
21. Oligodeoxynucleotide stability in subcellular extracts and culture media
22. Stability of antisense DNA oligodeoxynucleotide analogs in cellular-extracts and sera
23. Oligonucleotide analogs as potential chemotherapeutic-agents
24. Antisense oligonucleotides
25. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
26. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells
27. Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length
28. Attenuation of cytomegalovirus-induced endothelial intercellular adhesion molecule-1 mRNA/protein expression and T lymphocyte adhesion by a 2′-O-methoxyethyl antisense oligonucleotide
29. C-myc antisense limits rat liver regeneration and indicates role for C-myc in regulating cytochrome P-450 3A activity
30. In vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-alpha
31. Optimizing the cell efficacy of synthetic ribozymes - site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb
32. Chemical modification of hammerhead ribozymes - catalytic activity and nuclease resistance
33. Intracellular metabolism of a 2′-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis
34. Biodegradable polymer matrices for the sustained exogenous delivery of a biologically active C-myc hammerhead ribozyme
35. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes
36. Phosphorothioate ribozyme against the conserved sequence in V3 loop of HIV-1
37. Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA
38. Numbering system for the hammerhead
39. Antisense oligonucleotides as therapeutic agents - is the bullet really magical?
40. Cellular uptake and intracellular fate of antisense oligonucleotides
41. Characterization of oligonucleotide transport into living cells
42. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems
43. Intracellular-distribution of microinjected antisense oligonucleotides
44. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides
45. Inhibition of protein-kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
46. A single-injection protein kinase A directed antisense treatment to inhibit tumor growth
47. Lipid-based systems for the intracellular delivery of genetic drugs
48. In vitro transport and delivery of antisense oligonucleotides
49. Preparation and application of liposome-incorporated oligodeoxynucleotides
50. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu
51. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells
52. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides
53. Specific inhibition of macrophage TNF-alpha expression by in vivo ribozyme treatment
54. Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipooxygenase expression in vascular smooth muscle
55. Effect of cationic cholesterol derivatives on gene-transfer and protein kinase C activity
56. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids
57. Cell-specific optimization of phosphorothioate antisense oligodeoxynucleotide delivery by cationic lipids
58. A non-antisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells
59. Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity
60. Lipoplexes and tumours: a review
61. Fate and behavior of liposomes in vivo: a review of controlling factors
62. Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: in vivo-in vitro differences
63. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
64. Inhibition of TNF-alpha secretion by murine macrophages following in vivo and in vitro ribozyme treatment
65. Specific inhibition of macrophage TNF-alpha expression by in vivo ribozyme treatment
66. pH-Sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples
67. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides
68. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery
69. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers
70. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture
71. Dendrimer delivery of oligonucleotides
72. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers
73. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro
74. Neurite outgrowth in peripherin-depleted PC12 cells
75. Enhanced anti-tumor effects with microencapsulated C-myc antisense oligonucleotide
76. Microparticles of poly(dl-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery
77. Biodegradable poly(l-lactic acid) matrices for the sustained delivery of antisense oligonucleotides
78. Histologic comparison of polylactic and polyglycolic acid sutures
79. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues
80. Biosynthetic polyhydroxyalkanoates and their potential in drug delivery
81. Ribozymes: structure and mechanism in RNA catalysis
82. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres
83. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides
84. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake
85. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides
86. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-Ras-mediated cell proliferation and tumorigenicity in nude mice
87. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody
88. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages
89. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells
90. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages - selective and efficient elimination of the parasite
91. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo
92. Gene repair using chimeric RNA-DNA oligonucleotides
93. pH-Sensitive liposomes for receptor-mediated delivery to chicken hepatoma (LMH) cells
94. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA
95. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates
96. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells
97. In vivo protein transduction: delivery of a biologically active protein into the mouse
98. Brain as a unique antisense environment
99. Antisense technologies have a future fighting neurodegenerative diseases
100. In vivo imaging of oligonucleotides with positron emission tomography
101. Transferrin receptor on endothelium of brain capillaries
102. 125[I]transferrin through the rat blood-brain barrier
103. Complete inactivation of target messenger-RNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates
104. 32[P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin monoclonal-antibody conjugate
105. Oligonucleotide delivery: uptake of rat transferrin receptor antibody (OX-26) conjugates into an in vitro immortalized cell line model of the blood-brain barrier
106. 3[H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system
107. CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide, Naunyn-Schmiedeberg
108. Dopamine D-3 receptor antisense administration reduces basal c-fos and NGFI-B mRNA levels in the rat forebrain
109. Critical issues in the antisense inhibition of brain gene expression in vivo: experiences targeting the 5-HT1A receptor
110. Penetration of oligonucleotides into mouse organism through mucosa and skin
111. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
112. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes
113. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI alpha subunit of protein kinase A after oral administration
114. Interaction of oligonucleotide-conjugates with the dipeptide transporter system in Caco-2 cells
115. Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells